Latest Perspectives for Mineralocorticoid Receptor (MR) Antagonist, Finerenone

Bando H

Published on: 2024-07-05

Abstract

As a mineralocorticoid receptor (MR) antagonist, finerenone has been introduced for clinical practice, which contributes various benefits for type 2 diabetes (T2D), chronic kidney disease (CKD), diabetic kidney disease (DKD), and hypertension. It shows clinically decreasing risk for renal and cardiovascular outcomes. Using the National Health and Nutrition Examination Survey (NHANES) data sets, meaningful 2 studies were conducted for finerenone. They are FIDELIO-DKD and FIGARO-DKD, which are wholly called as FIDELITY trials. A variety of mechanisms would exist for MR overactivation in diabetic patients. Especially, it can focus on post translation of MR modifications and O-linked N-acetylglucosamine (O-GlcNAc) modification.